Abrégé

The disclosed method for classifying microorganisms contained in a sample comprises: preparing a slide of the sample; acquiring at least one digital image of the slide; and implementing, with a computer, a model for predicting the class of the microorganisms depending on the acquired image. According to the invention, said image is subdivided into sub-images and each sub-image is sub-divided into patches, and: A. for each patch, a microorganism feature extractor is applied, the feature extractor forming a convolutional part of a first convolutional neural network trained on patches annotated individually with at least one class; B. for each sub-image, a second neural network connected to the extractor is applied, the second neural network comprising an upstream pooling layer and one or more downstream layers comprising a layer for predicting at least one class, and being trained on training sub-images globally; and C. for the acquired image: F.a. calculating a feature vector calculated for the sub-images; F.b. applying a model for predicting at least one class for the microorganisms.

Classes IPC  ?

• G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p. ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersectionsAnalyse de connectivité, p. ex. de composantes connectées
• G06V 10/50 - Extraction de caractéristiques d’images ou de vidéos en effectuant des opérations dans des blocs d’imagesExtraction de caractéristiques d’images ou de vidéos en utilisant des histogrammes, p. ex. l’histogramme de gradient orienté [HoG]Extraction de caractéristiques d’images ou de vidéos en utilisant l’addition des valeurs d’intensité d’imageAnalyse de projection
• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
• G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires
• C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions

Abrégé

A method for in vitro or ex vivo assessment of the risk of complications in a patient admitted to a healthcare facility includes measuring the viral load of at least one torque teno virus (TTV) in a biological sample of the patient, wherein the patient is not undergoing immunosuppressive treatment.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

The invention relates to a method for characterising microorganisms which comprises: A. for each wavelength of a predetermined set of wavelengths comprising at least one wavelength, acquiring a holographic digital image, generating a focused image by computer means, each pixel of which image comprises an amplitude value and a phase value, and segmenting the focused image so as to extract portions corresponding to microorganisms; and B. characterising the microorganisms by computer means, according to the focused image portions. According to the invention, prior to the characterisation or prior to the segmentation or prior to the generation of the focused image, the method comprises correcting optical aberrations of the acquisition device by computer means, and the characterisation of the microorganisms comprises applying a digital model to these portions having as descriptors the amplitude and/or phase values of each wavelength of the predetermined set of wavelengths.

Classes IPC  ?

• G03H 1/00 - Procédés ou appareils holographiques utilisant la lumière, les infrarouges ou les ultraviolets pour obtenir des hologrammes ou pour en obtenir une imageLeurs détails spécifiques
• G03H 1/04 - Procédés ou appareils pour produire des hologrammes
• G03H 1/26 - Procédés ou appareils adaptés spécialement pour produire des hologrammes multiples ou pour en obtenir des images, p. ex. procédés pour l'holographie à plusieurs couleurs
• G01N 15/1433 - Traitement du signal utilisant la reconnaissance d’image
• G01N 15/1434 - Dispositions optiques
• G01N 15/10 - Recherche de particules individuelles
• G03H 1/08 - Procédés ou appareils pour produire des hologrammes pour faire des hologrammes synthétiques
• G06T 7/00 - Analyse d'image
• G06V 10/143 - Détection ou éclairage à des longueurs d’onde différentes
• G06V 10/22 - Prétraitement de l’image par la sélection d’une région spécifique contenant ou référençant une formeLocalisation ou traitement de régions spécifiques visant à guider la détection ou la reconnaissance
• G06V 10/24 - Alignement, centrage, détection de l’orientation ou correction de l’image
• G06V 10/26 - Segmentation de formes dans le champ d’imageDécoupage ou fusion d’éléments d’image visant à établir la région de motif, p. ex. techniques de regroupementDétection d’occlusion
• G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p. ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersectionsAnalyse de connectivité, p. ex. de composantes connectées
• C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique

Abrégé

An in vitro or ex vivo method for determining the risk of incidence of a healthcare-associated infection in a patient, including a step of measuring the expression of at least one gene encoding a pro-inflammatory cytokine receptor located on chromosome 2 in the region 2q11-2q12, in a biological sample from the patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• C12Q 1/6851 - Amplification quantitative

Abrégé

A method for classifying at least one input image representing a target particle in a sample, involves implementing, by data processing of a client, steps of: (b) extracting the characteristic map of the target particle by a convolutional neural network pre-trained on a base of public images; (c) classifying the input image according to the extracted characteristic map.

Classes IPC  ?

• G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
• G06T 7/10 - DécoupageDétection de bords
• G06V 10/24 - Alignement, centrage, détection de l’orientation ou correction de l’image
• G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p. ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersectionsAnalyse de connectivité, p. ex. de composantes connectées
• G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”

Abrégé

The invention relates to a method for characterising microorganisms present in a biological sample, the method comprising acquiring a live holographic digital image of the sample, generating a focused image by using a digital model for reconstructing the focused image and characterising the bacteria on the basis of the focused image. According to the invention, prior to the holographic image being acquired, a plurality of calibration objects are provided in the acquisition field of view, which objects have a previously characterised dimension and refractive index and a shape chosen so that the interference patterns of the objects can be calculated using an image forming model for incorporating optical aberrations of the acquisition device. Prior to the focused image being computer generated, the optical aberrations are qualified according to the interference patterns of the objects and the calculated interference patterns and the digital model for reconstructing the focused image incorporates the quantified optical aberrations.

Classes IPC  ?

• G03H 1/00 - Procédés ou appareils holographiques utilisant la lumière, les infrarouges ou les ultraviolets pour obtenir des hologrammes ou pour en obtenir une imageLeurs détails spécifiques
• G03H 1/04 - Procédés ou appareils pour produire des hologrammes
• G03H 1/08 - Procédés ou appareils pour produire des hologrammes pour faire des hologrammes synthétiques
• G01N 15/02 - Recherche de la dimension ou de la distribution des dimensions des particules
• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
• G01N 15/10 - Recherche de particules individuelles
• G06T 7/00 - Analyse d'image
• G06V 10/24 - Alignement, centrage, détection de l’orientation ou correction de l’image
• G06T 5/00 - Amélioration ou restauration d'image
• G02B 21/00 - Microscopes

Abrégé

A digital holographic imaging technique, includes iterative steps of: a) through back-propagation to the object coordinate of a hologram field comprising a spatial distribution of amplitude corresponding to the spatial distribution of intensity of the hologram and a spatial distribution of phase, determining an object field involving a spatial distribution of absorption and of phase shift of the imaged object, b) thresholding the values of the spatial distribution of absorption and of phase shift by decreasing the values to below a respective threshold, the thresholds decreasing in each iteration, c) through repropagation of the object field to the hologram coordinate, determining a modified hologram field comprising a modified spatial distribution of amplitude and a modified spatial distribution of phase, d) replacing the spatial distribution of phase of the hologram field with the modified spatial distribution of phase, the spatial distribution of phase shift and of absorption of the imaged object being those of the object field of the last iteration.

Classes IPC  ?

• G03H 1/08 - Procédés ou appareils pour produire des hologrammes pour faire des hologrammes synthétiques
• G03H 1/00 - Procédés ou appareils holographiques utilisant la lumière, les infrarouges ou les ultraviolets pour obtenir des hologrammes ou pour en obtenir une imageLeurs détails spécifiques
• G03H 1/04 - Procédés ou appareils pour produire des hologrammes

Abrégé

A method for classifying at least one input image containing a target particle in a sample, involves implementing, via data-processing of a client, steps of: (b) extracting a vector of characteristics of the target particle, the characteristics being numerical coefficients each associated with one elementary image of a set of elementary images each representing a reference particle, such that a linear combination of the elementary images weighted by the coefficients approximates the representation of the target particle in the input image; (c) classifying the input image depending on the extracted vector of characteristics.

Classes IPC  ?

• G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires
• G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”

Abrégé

A method for classifying at least one input image representing a target particle in a sample involves implementing, by data processing a client, steps of: (B) extracting a characteristic map of the target particle from the input image; (c) reducing the number of variables in the extracted characteristic map, using the t-SNE algorithm; (d) classifying, unsupervised, the input image based on the characteristic map having a reduced number of variables.

Classes IPC  ?

• G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
• G06T 7/11 - Découpage basé sur les zones
• G06V 10/24 - Alignement, centrage, détection de l’orientation ou correction de l’image
• G06V 10/771 - Sélection de caractéristiques, p. ex. sélection des caractéristiques représentatives à partir d’un espace multidimensionnel de caractéristiques
• G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires

Abrégé

A method for classifying a sequence of input images representing a target particle in a sample over time, includes the following steps performed by the data processing of a client, namely: (b) concatenation of the input images in the sequence as a three-dimensional stack; (c) direct classification of the three-dimensional stack using a convolutional neural network, CNN.

Classes IPC  ?

• G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires
• G06V 10/77 - Traitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source
• G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux

Abrégé

An in vitro or ex vivo method for determining the risk of complication in a patient, including a step of measuring the expression of C3AR1 in a biological sample from the patient.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries

Produits et services

Chemicals for use in industry and science; Chemical additives for food; Chemicals for use in agriculture. Veterinary preparations; Pharmaceuticals; Sanitary preparations for medical purposes; Dietetic foods adapted for medical purposes; Dietetic food adapted for veterinary use; Dietary supplements for human beings and animals; Plasters, materials for dressings. Scientific apparatus and instruments; Weighing apparatus and instruments; Measuring apparatus; Checking (supervision) apparatus and instruments; Data processing equipment; Software; Nautical apparatus and instruments; Surveying apparatus and instruments; Photographic apparatus and instruments; Cinematographic cameras; Optical apparatus and instruments; Measuring apparatus and instruments; Sound recording apparatus; Apparatus for transmission of communication; Apparatus for the transmission of images; Sound reproduction apparatus; Sound transmitting apparatus; Sound and picture recording apparatus; Apparatus for the reproduction of images. Artificial teeth; Surgical apparatus and instruments; Medical apparatus and instruments; Dental equipment; Artificial limbs; Artificial eyes. Teaching; Training; Entertainment services. Scientific technological services; Research and development services; Design services; Industrial analysis and research services; Software design and development. Medical services; Animal healthcare services; Blood bank services; Human tissue bank services.

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of CIITA in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

An in vitro or ex vivo method for determining the risk of incidence of a care-related infection includes a step of measuring the expression of CD177 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

An in vitro or ex vivo method for determining the risk of incidence of a healthcare-associated infection includes a step of measuring the expression of TAP2 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• C12Q 1/6813 - Tests d’hybridation
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]

Abrégé

An in vitro or ex vivo method, based on the measurement of the expression of cytokine(s), from a patient's blood sample, incubated with a stimulus, for determining the risk of occurrence of a healthcare-associated infection in the patient, within seven days following the day on which the collection of the biological sample has been performed from the patient.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention relates to a method for in vitro or ex vivo assessment of the risk of complications in a patient admitted to a healthcare facility, the method comprising measuring the viral load of at least one torque teno virus (TTV) in a biological sample of said patient, characterised in that said patient is not undergoing immunosuppressive treatment.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

An in vitro or ex vivo method for determining the risk of occurrence of a healthcare-associated infection in a patient, including a step of measuring the expression of CX3CR1, in a biological sample of said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne

Abrégé

The invention relates to a method for classifying a sequence of input images representing a target particle (11a-11f) in a sample (12) over time, the method being characterized in that it comprises the following steps performed by the data processing means (20) of a client (2), namely: (b) concatenation of the input images in the sequence as a three-dimensional stack; (c) direct classification of the three-dimensional stack using a convolutional neural network, CNN

Classes IPC  ?

• G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
• G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques

Abrégé

The invention relates to a method for classifying at least one input image containing a target particle (11a-11f) in a sample (12), the method being characterized in that it involves implementing, via data-processing means (20) of a client (2), steps of: (b) extracting a vector of characteristics of said target particle (11a-11f), said characteristics being numerical coefficients each associated with one elementary image of a set of elementary images each representing a reference particle, such that a linear combination of said elementary images weighted by said coefficients approximates the representation of said target particle (11a-11f) in the input image; (c) classifying said input image depending on said extracted vector of characteristics.

Classes IPC  ?

• G06V 30/19 - Reconnaissance utilisant des moyens électroniques
• G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires

Abrégé

The invention relates to a method for classifying at least one input image representing a target particle (11a-11f) in a sample (12), the method being characterized in that it involves implementing, by data processing means (20) of a client (2), steps of: (b) extracting the characteristic map of the target particle (11a-11f) by means of a convolutional neural network pre-trained on a base of public images; (c) classifying the input image according to said extracted characteristic map.

Classes IPC  ?

• G06V 10/22 - Prétraitement de l’image par la sélection d’une région spécifique contenant ou référençant une formeLocalisation ou traitement de régions spécifiques visant à guider la détection ou la reconnaissance
• G06V 10/60 - Extraction de caractéristiques d’images ou de vidéos relative aux propriétés luminescentes, p. ex. utilisant un modèle de réflectance ou d’éclairage
• G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires
• G06V 10/762 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant le regroupement, p. ex. de visages similaires sur les réseaux sociaux

Abrégé

A digital holographic imaging technique, with iterative steps of: a) through back-propagation to the object coordinate of a hologram field comprising a spatial distribution of amplitude corresponding to the spatial distribution of intensity of the hologram and a spatial distribution of phase, determining (S03a) an object field involving a spatial distribution of absorption and of phase shift of the imaged object, b) thresholding (S03b) the values of the spatial distribution of absorption and of phase shift by decreasing the values to below a respective threshold, the thresholds decreasing in each iteration, c) through repropagation of the object field to the hologram coordinate, determining (S03c) a modified hologram field comprising a modified spatial distribution of amplitude and a modified spatial distribution of phase, d) replacing (S03d) the spatial distribution of phase of the hologram field with the modified spatial distribution of phase, the spatial distribution of phase shift and of absorption of the imaged object being those of the object field of the last iteration.

Classes IPC  ?

• G03H 1/00 - Procédés ou appareils holographiques utilisant la lumière, les infrarouges ou les ultraviolets pour obtenir des hologrammes ou pour en obtenir une imageLeurs détails spécifiques
• G03H 1/04 - Procédés ou appareils pour produire des hologrammes
• G03H 1/08 - Procédés ou appareils pour produire des hologrammes pour faire des hologrammes synthétiques

Abrégé

The invention relates to a method for classifying at least one input image representing a target particle (11a-11f) in a sample (12), the method being characterized in that it involves implementing, by data processing means (20) of a client (2), steps of: (B) extracting a characteristic map of the target particle (11a-11f) from the input image; (c) reducing the number of variables in the extracted characteristic map, using the t-SNE algorithm; (d) classifying, unsupervised, the input image based on the characteristic map having a reduced number of variables.

Classes IPC  ?

• G06K 9/62 - Méthodes ou dispositions pour la reconnaissance utilisant des moyens électroniques
• G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of CD177 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of CIITA in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of TAP2 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of C3AR1 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention relates to an in vitro or ex vivo method for determining the risk of a care-related infection in a patient, comprising a step of measuring the expression of at least one gene encoding a pro-inflammatory cytokine receptor, located in the region 2q11-2q12 of chromosome 2 in a biological sample of said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

A support for a multiplex binding experiment is functionalized with at least two different polypeptides. The polypeptides are provided in a reaction mixture along with their cognate binding partners. The polypeptides have high affinity for their cognate binding partners provided in the reaction mixture. The polypeptides and their cognate binding partners can be used in immunoassays.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention provides for a microfluidic droplet-based assay process and apparatus, wherein the process comprises the step of creating several assay droplets (18) containing paramagnetic particles (22, 22′), detectable markers (24), and at least one biological cell (10), wherein the paramagnetic particles (22, 22′) and the detectable markers (24) are able to bind with a target analyte (16) released by the cell, wherein the process includes storing several assay droplets along a horizontal storage plane, includes the generation of a magnetic field through the stored assay droplets, and includes detecting a physical characteristic of the detectable markers contained in a given assay droplet by optical imaging of the detectable markers, characterized in that the generation of a magnetic field generates a magnetic field such that the paramagnetic particles are attracted towards a lateral and inferior portion of the given stored assay droplet in which they are contained.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 21/64 - FluorescencePhosphorescence

Abrégé

The present invention relates to an in vitro or ex vivo method based on the measurement of the expression of cytokine(s) from a blood sample of a patient, incubated with a stimulus, for determining the risk of incidence of a care-associated infection in the patient within a period of seven days from the day the blood sample was taken from the patient.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to an in vitro or ex vivo method based on the measurement of the expression of cytokine(s) from a blood sample of a patient, incubated with a stimulus, for determining the risk of incidence of a care-associated infection in the patient within a period of seven days from the day the blood sample was taken from the patient.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a method for detecting the proportion of Gram-positive and Gram-negative bacteria in a complex sample. The bacteria are detected according to the Gram signal thereof. The invention enables distinction between species of Gram-positive bacteria and species of Gram-negative bacteria in a complex sample. The invention also relates to a kit for marking Gram-positive and Gram-negative bacteria, particularly for use in flow cytometry, particularly for complex samples such as human or animal microbiota samples.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-associated infection in a patient, involving a step of measuring the expression of CX3CR1 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

in vitroex vivoex vivo method for determining the risk of incidence of a care-associated infection in a patient, involving a step of measuring the expression of CX3CR1 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

Classes IPC  ?

• C12N 9/84 - Penicillinamidase
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• A61K 38/50 - Hydrolases (3) agissant sur des liaisons carbone-azote autres que des liaisons peptidiques (3.5), p. ex. asparaginase
• C12N 9/86 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides cycliques, p. ex. pénicillinase
• A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present invention concerns a support for a multiplex binding experiment functionalized with at least two different polypeptides having high affinity to their cognate binding partners provided in a reaction mixture, and their use in e.g. immunoassays.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention concerns a support for a multiplex binding experiment functionalized with at least two different polypeptides having high affinity to their cognate binding partners provided in a reaction mixture, and their use in e.g. immunoassays.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention provides for a microfluidic droplet-based assay process and apparatus, wherein the process comprises the step of creating several assay droplets (18) containing paramagnetic particles (22, 22'), detectable markers (24), and at least one biological cell (10), wherein the paramagnetic particles (22, 22') and the detectable markers (24) are able to bind with a target analyte (16) released by the cell, wherein the process includes storing several assay droplets along a horizontal storage plane, includes the generation of a magnetic field through the stored assay droplets, and includes detecting a physical characteristic of the detectable markers contained in a given assay droplet by optical imaging of the detectable markers, characterized in that the generation of a magnetic field generates a magnetic field such that the paramagnetic particles are attracted towards a lateral and inferior portion of the given stored assay droplet in which they are contained.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées

Abrégé

The present invention relates to a method for determining in vitro or ex vivo the immune status of an individual, preferably a patient, comprising a step of detecting and/or quantifying the expression of one or more HERV/MaLR sequences in a biological sample of said individual. The invention also relates to the tools for implementing said method and to the uses thereof.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to a method for detecting the proportion of Gram-positive and Gram-negative bacteria in a complex sample. The bacteria are detected according to the Gram signal thereof. The invention enables distinction between species of Gram-positive bacteria and species of Gram-negative bacteria in a complex sample. The invention also relates to a kit for marking Gram-positive and Gram-negative bacteria, particularly for use in flow cytometry, particularly for complex samples such as human or animal microbiota samples.

Classes IPC  ?

• C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

Classes IPC  ?

• C12N 9/86 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides cycliques, p. ex. pénicillinase
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

A device for acquisition of particles present in a sample includes a spatially coherent light source, an optical system, and an image sensor placed in the focal plane of the optical system. The image sensor is configured to capture an intensity image. A computational unit of the device is configured to construct a series of electromagnetic propagation matrices obtained for a plurality of defocusing offsets relative to a plane of focus of the optics. The computational unit is also configured to determine a first average focused electromagnetic matrix for the particles from the series of electromagnetic matrices, identifying at least one of the particles in the first electromagnetic matrix and storing the coordinates of said particle, and determining a second electromagnetic matrix at a distance of focus on a particle identified from the components of the series of electromagnetic matrices having the stored coordinates.

Classes IPC  ?

• G03H 1/08 - Procédés ou appareils pour produire des hologrammes pour faire des hologrammes synthétiques
• G03H 1/04 - Procédés ou appareils pour produire des hologrammes
• G01N 15/14 - Techniques de recherche optique, p. ex. cytométrie en flux
• G06T 7/55 - Récupération de la profondeur ou de la forme à partir de plusieurs images
• C12Q 1/20 - Test de l'activité antimicrobienne d'un matériau utilisant des milieux polyvalents
• G01N 15/10 - Recherche de particules individuelles
• G01N 21/45 - RéfringencePropriétés liées à la phase, p. ex. longueur du chemin optique en utilisant des méthodes interférométriquesRéfringencePropriétés liées à la phase, p. ex. longueur du chemin optique en utilisant les méthodes de Schlieren
• G06T 7/00 - Analyse d'image

Produits et services

Dental preparations and articles, and medicated dentifrices; Diagnostic preparations and materials; Pharmaceuticals and natural remedies; Cellular function activating agents for medical purposes; Drug delivery agents that facilitate the delivery of pharmaceutical preparations; Yeast extracts for medical, veterinary or pharmaceutical purposes; Blood protein fractions; Microbicides; Blood plasma; Bacteriological preparations for medical purposes; Bacteriological preparations for veterinary purposes; Bacterial preparations for veterinary purposes; Bacterial preparations for medical and veterinary use; Bacterial preparations for medical purposes; Enzyme preparations for medical purposes; Enzyme preparations for veterinary purposes; Veterinary preparations and substances; Medical preparations; Mineral preparations for medical purposes; Preparations for use in naturopathy; Medicinal healthcare preparations; Pharmaceutical preparations for animals; Pharmaceutical preparations for veterinary use; Oral vaccine preparations; Diagnostic radiopharmaceutical preparations; Veterinary preparations; Reagents for use in medical genetic testing; Reagents for use in veterinary genetic testing; Reagents for medical use; Nucleic acid sequences for medical and veterinary purposes; Vaccines; Vaccines for human use; none of the aforementioned goods in respect of ophthalmology or eye care. Scientific and laboratory devices for treatment using electricity; Measuring, detecting and monitoring instruments, indicators and controllers; none of the aforementioned goods in respect of ophthalmology or eye care. Education, entertainment and sport services; Education, entertainment and sports. IT services; Scientific technological services; Design of instruments; Design of diagnostic apparatus and equipment; Constructing an internet platform for electronic commerce; New product design; Design of pipelines; Product design; Design of industrial products; Computer website design; Computer specification design; Design of measurement systems; Computer system design; Design services for data processing systems; Engineering design and consultancy; Design and development of diagnostic apparatus; Design and development of medical diagnostic apparatus; Database design and development; Design and development of testing and analysis methods; Design and development of new products; Design and development of new technology for others; Product design and development; Design and testing for new product development; Design and testing of new products; Scientific and technological design; Product development consultation; Creating and designing website-based indexes of information for others [information technology services]; Development of diagnostic apparatus; Product development; Product development for others; Providing information in the field of product design; Providing information in the field of product development; Research relating to design; Product research and development; Design feasibility studies; Design services relating to data processing test tools; Design services relating to plant for the biotechnology industry; Design services relating to the creation of elementary cells; Design services relating to data processing tools; Design services relating to the publication of documents; Design services relating to data processors; Computer design services; Scientific design services; Technical design services relating to sanitary apparatus and installations; Design services relating to computer hardware and to computer programmes; Engineering consultancy relating to design; Technological services relating to design; Scientific services and design relating thereto; Technological services and design relating thereto; Design services relating to process systems for the biotechnology industry; none of the aforementioned services in respect of ophthalmology or eye care. Animal healthcare services; Human healthcare services; none of the aforementioned services in respect of ophthalmology or eye care.

Abrégé

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a Verona integron-encoded metallo-β-lactamase (VIM-2) variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

Classes IPC  ?

• C12N 9/86 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides cycliques, p. ex. pénicillinase
• A61K 31/43 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes
• A61K 38/50 - Hydrolases (3) agissant sur des liaisons carbone-azote autres que des liaisons peptidiques (3.5), p. ex. asparaginase
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.

Classes IPC  ?

• C12N 9/86 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides cycliques, p. ex. pénicillinase
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p. ex. kétorolac, physostigmine
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/546 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine contenant d'autres hétérocycles, p. ex. céphalotine
• A61K 38/50 - Hydrolases (3) agissant sur des liaisons carbone-azote autres que des liaisons peptidiques (3.5), p. ex. asparaginase

Abrégé

The invention relates to the field of probiotics and provides a Lactobacillus paracasei strain capable of improving the immune response to a viral-bacterial coinfection.

Classes IPC  ?

• A61K 35/74 - Bactéries
• A61P 31/04 - Agents antibactériens
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

The invention relates to a device (10) for acquiring particles (11a-11f) present in a sample (12), said acquiring device including a spatially coherent light source (15), a lens, an image sensor (16) that is placed in the focal plane of the lens and configured to capture an intensity image and a computational unit that is configured: to construct a series of propagation electromagnetic matrices obtained for a plurality of defocalization offsets with respect to a focal plane of the lens; to determine, for the particles, a first average defocalized electromagnetic matrix on the basis of the series of electromagnetic matrices; to identify at least one of the particles in the first electromagnetic matrix and to store in memory the coordinates of said particle; and to determine, for a particle identified on the basis of components of the series of electromagnetic matrices having the coordinates stored in memory, a second electromagnetic matrix at a focal distance.

Classes IPC  ?

• G01N 21/45 - RéfringencePropriétés liées à la phase, p. ex. longueur du chemin optique en utilisant des méthodes interférométriquesRéfringencePropriétés liées à la phase, p. ex. longueur du chemin optique en utilisant les méthodes de Schlieren
• G03H 1/00 - Procédés ou appareils holographiques utilisant la lumière, les infrarouges ou les ultraviolets pour obtenir des hologrammes ou pour en obtenir une imageLeurs détails spécifiques
• G03H 1/08 - Procédés ou appareils pour produire des hologrammes pour faire des hologrammes synthétiques

Abrégé

The invention relates to a nanoparticle which comprises an assembly of encapsulin monomers and in which a peptide has been inserted into the amino acid sequence of at least one of said encapsulin monomers, the insertion site being located outside domain A of the encapsulin monomer, the nanoparticle further comprising an internal protein.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
• A61K 39/02 - Antigènes bactériens
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments

Abrégé

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability.

Classes IPC  ?

• C12N 9/86 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides cycliques, p. ex. pénicillinase

Abrégé

The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a VIM-2 variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.

Classes IPC  ?

• C12N 9/86 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides cycliques, p. ex. pénicillinase

Produits et services

Dietary supplements and dietetic preparations; Sanitary preparations and articles; Dental preparations and articles, and medicated dentifrices; Pest control preparations and articles; Hygienic preparations and articles; Dental preparations and articles; Live organs and tissues for surgical purpose; Medical dressings, coverings and applicators; Diagnostic preparations and materials; Pharmaceuticals and natural remedies; Marine antifoulants; Cellular function activating agents for medical purposes; Chlorine detoxification agents for medical purposes; Arsenic detoxification agents for medical purposes; Benzol detoxification agents for medical purposes; Drug delivery agents that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; Alcohol for pharmaceutical purposes; Pain relief medication for veterinary purposes; Antibiotics for fish; Animal dips [preparations]; Cachets for medicinal purposes; Cachets for pharmaceutical purposes; Capsules for medicines; Capsules sold empty for pharmaceuticals; Reconstituted cells for clinical treatments for skin care; Reconstituted cells for medical treatments for skin care; Stem cells for medical purposes; Stem cells for veterinary purposes; Living cells for veterinary use; Tobacco-free cigarettes for medical purposes; Bone cement for surgical and orthopaedic purposes; Bone cement for medical purposes; Cement for animal hooves; Surgical cements; Bone cements for surgical purposes; Bone cements for orthopaedic purposes; Collagen for medical purposes; Surgical glues; Collodion for pharmaceutical purposes; Antibiotic food supplements for animals; Nutritional supplements for veterinary use; Feed supplements for veterinary use; Blood components; Chemical contraceptives; Crystals for therapeutic purposes; Bone growth media consisting of biological materials for medical purposes; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Dextrins for pharmaceutical use; Enzymes for medical purposes; Enzymes for veterinary purposes; Cellulose esters for pharmaceutical purposes; Bark extract for medical use; Bark extract for veterinary use; Yeast extracts for medical, veterinary or pharmaceutical purposes; Contraceptive sponges; Chemical contraceptive sponges; Cellulose ethers for pharmaceutical purposes; Blood protein fractions; Petroleum jelly for medical or veterinary purposes; Scrubs [preparations] for medical use; Breath-freshening chewing gum for medicinal purposes; Greases for medical purposes; Greases for veterinary purposes; Vascular grafts [living tissue]; Gelatine for medical purposes; Radiotherapeutic hormones; Sandalwood oil for medical, pharmaceutical and veterinary purposes; Castor oil as a coating for pharmaceuticals; Medicated baby oils; Haemoglobin; Biological indicators for monitoring sterilization processes for medical or veterinary purposes; Isotopes for medical purposes; Yeast for medical, veterinary or pharmaceutical purposes; Impregnated medicated wipes; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Medicated after-shave lotions; Lotions for veterinary purposes; Radio-isotope markers for therapeutic or diagnostic use; Microbicides; Contraceptive foams; Cardiovascular agents for medical purposes; Paracetamol preparations for intravenous administration; Paracetamol preparations for oral administration; Paracetamol modified release preparations; Medicines for veterinary purposes; Pheromones; Blood plasma; Bacterial poisons; Herbal anti-itch ointments for pets; Herbal sore skin ointments for pets; Bark powder for medical use; Pearl powder for medical purposes; Bark powder for veterinary use; Bacterial preparations for medical purposes; Bacterial preparations for medical and veterinary use; Bacterial preparations for veterinary purposes; Bacteriological preparations for medical purposes; Bacteriological preparations for veterinary purposes; Biochemical preparations for medical use; Biochemical preparations for veterinary use; Mixed biological preparations for medical purposes; Biological preparations for medical purposes; Biological preparations for veterinary purposes; Chemical preparations for medical purposes; Chemical preparations for veterinary purposes; Amino acid preparations for medical purposes; Amino acid preparations for veterinary use; Preparations of trace elements for human and animal use; Douching preparations for medical purposes; Medicated toiletry preparations; Trichomycin preparations; Cantharides preparations for medical use; Cantharides preparations for veterinary use; Trace element preparations for human use; Methionine preparations; Mineral food preparations for medical purposes; Antipyretic preparations; Corn remedies; Organotherapeutics; Injectable dermal filler; Trace element preparations for use by animals; Panthenol preparations for medical use; Enzyme preparations for medical purposes; Enzyme preparations for veterinary purposes; Veterinary preparations and substances; Mineral preparations for medical purposes; Medical preparations; Preparations for use in naturopathy; Medicated eye-washes; Medicinal healthcare preparations; Pharmaceutical preparations for animals; Pharmaceutical preparations for treating the symptoms of radiation sickness; Tryptophane preparations; Pharmaceutical preparations for veterinary use; Rehydration preparations; Enema preparations; Bath preparations for medical purposes; Oral vaccine preparations; Diagnostic radiopharmaceutical preparations; Therapeutic preparations for the bath; Medicinal clay preparations; Breath refreshers for medical purposes; Radioactive substances for medical purposes; Veterinary preparations; Reagents for use in medical genetic testing; Reagents for use in veterinary genetic testing; Reagents for medical use; By-products of the processing of cereals for medical purposes; Cord blood for medical purposes; Cord blood; Blood for medical purposes; Leeches for medical purposes; Bath salts for medical purposes; Pre-filled syringes for medical purposes; Medicated shampoos; Medicated shampoos for pets; Medicated dry shampoos; Nucleic acid sequences for medical and veterinary purposes; Cooling sprays for medical purposes; Feeding stimulants for animals; Blood substitutes; Milk sugar for medical purposes [lactose]; Chromatographic supports for medical use; Trypsins for medical purposes; Urease for medical purposes; Vaccines; Vaccines for human use. Scientific research and laboratory apparatus, educational apparatus and simulators; Recorded content; Information technology and audio-visual, multimedia and photographic devices; Scientific and laboratory devices for treatment using electricity; Measuring, detecting and monitoring instruments, indicators and controllers; Information technology and audiovisual equipment. Publishing and reporting; Education, entertainment and sport services; Organisation of conferences, exhibitions and competitions; Audio, video and multimedia production, and photography; Education and instruction services; Hosting [organising] awards; Education, entertainment and sports. Design services; Scientific technological services; Testing, authentication and quality control; IT services. Animal healthcare services; Human healthcare services; Human hygiene and beauty care; Agriculture, aquaculture, horticulture and forestry services.